Short-term morbidity from CT-planned transperineal I-125 prostate implants.
OBJECTIVE
To summarize short-term morbidity and tumor response following transperineal CT-guided I-125 prostate implantation.


METHODS
Twenty-one patients were treated with CT-based transperineal I-125 prostate implantation between June, 1988 and May, 1990. An average of 75 I-125 seeds were placed, with an average activity of .62 mCi/seed. Symptoms were quantified after interviewing each patient in detail.


RESULTS
Nearly all patients developed substantial dysuria, nocturia and frequency from 2-24 weeks following implantation. Urinary symptoms usually resolved within 4-6 months of implantation. The one year actuarial potency rate among 18 patients who were potent prior to implantation was 94%. By 6 months after implantation, 14/17 patients (82%) with Stage B tumors had complete regression of palpable disease. Of 17 patients with Stage A or B tumors who presented with an elevated PSA, 76% returned to the normal range within 6 months of implantation.


CONCLUSIONS
CT-guided transperineal prostate implants entail moderate, temporary urinary and rectral morbidity. Short-term tumor responses are encouraging.
Arterbery
V E
VE
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
Wallner
K
K
Roy
J
J
Fuks
Z
Z
D001918:Brachytherapy / Q000009:adverse effects*; D004542:Ejaculation; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014555:Urination Disorders / Q000209:etiology / Q000503:physiopathology